Cytarabine, Idarubicin, and Lenalidomide

The combination of cytarabine, idarubicin, and lenalidomide is an investigational treatment regimen that has been studied primarily for relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). This combination brings together conventional chemotherapy agents (cytarabine and idarubicin) with an immunomodulatory drug (lenalidomide). ## Components of the Combination **Cytarabine** is a standard chemotherapy drug used in AML treatment. It's a nucleoside analog that works by interfering with DNA synthesis, particularly affecting rapidly dividing cells like cancer cells[1][4]. It's commonly administered as part of various AML treatment regimens, either at standard doses or high doses depending on the specific protocol. **Idarubicin** is an anthracycline antineoplastic agent that is frequently used in AML treatment[2][5]. It works by intercalating DNA and inhibiting topoisomerase II, which disrupts DNA replication and transcription in cancer cells. **Lenalidomide** is an immunomodulatory drug that has been investigated as an addition to standard chemotherapy regimens to potentially improve outcomes in AML and MDS[1][3]. ## Clinical Evidence A phase I study evaluated the combination of lenalidomide with cytarabine/idarubicin salvage chemotherapy in patients with relapsed/refractory AML and high-risk MDS[1]. The study enrolled 33 patients (30 with AML, 3 with MDS) and determined that the maximum tolerated dose was: - Lenalidomide 25 mg/day on days 1-21 - Cytarabine 1 g/m² on days 5-8 - Idarubicin 8 mg/m² on days 5-7[1] The study reported: - Complete remission (CR) or CR with incomplete count recovery (CRi) was achieved in 18 patients (56%) - One-year overall survival was 24% - Two-year overall survival was 10% - Among responders who underwent allogeneic hematopoietic cell transplantation, one-year overall survival was 40%[1] ## Dosing Regimens Different dosing schedules have been investigated: - In one protocol, patients received lenalidomide orally once daily on days 1-21, cytarabine intravenously continuously over 24 hours on days 5-11, and idarubicin according to a specific schedule[8]. - The maximum tolerated dose from the phase I study was lenalidomide 25 mg/day on days 1-21, cytarabine 1 g/m² on days 5-8, and idarubicin 8 mg/m² on days 5-7[1]. ## Side Effects and Toxicity The combination therapy has significant toxicities. In the phase I study: - Dose-limiting toxicity was observed in eight patients, including four hematologic dose-limiting toxicities - Common non-hematologic serious adverse events included febrile neutropenia, rash, sepsis, and renal injury - Only 45% of patients were able to receive the planned 21 days of lenalidomide[1] ## Current Status and Applications This combination has shown clinical activity in relapsed/refractory AML and may be particularly valuable: - For patients who have relapsed after hematopoietic cell transplantation - As a bridge therapy to hematopoietic cell transplantation[1] The regimen continues to be investigated in clinical trials for AML and MDS, with ongoing research to determine optimal dosing, patient selection, and potential biomarkers of response.